Clinical trial

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

NCT00770848

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention AMG 102 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Mitoxantrone Normalized identity: mitoxantroneView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Prednisone Normalized identity: prednisoneView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-11-01

PhasePHASE1 / PHASE2

Conditions

Cancerverified · MONDO: cancer

Castrate-Resistant Prostate Cancerunresolved

Mestastatic Prostate Cancerunresolved

Prostate Cancerverified · MONDO: prostate cancer

Interventions

AMG 102DRUG

MitoxantroneDRUG · verified · RxNorm: mitoxantrone

PlaceboDRUG

PrednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

Amgenlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00770848 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.